About Us

size_1105x610

Adhering to the concept and spirit of continuous innovation, Based on science, create a better vision for mankind.

 

SciVision Biotech Inc. is a publicly listed company on the Taiwan Stock Exchange since 2013 (Stock Code: 1786), dedicated to the development and manufacturing of high-end medical-grade hyaluronic acid (HA) products.

From the very beginning, SciVision has built its foundation on the Cross-Linked Hyaluronic Acid Platform (CHAP)—a proprietary technology developed in-house to overcome long-standing limitations in traditional HA application. CHAP enables precise control over HA characteristics, significantly enhancing product performance and consistency. This core platform has supported the development of a wide portfolio of HA-based solutions across various medical and aesthetic applications.

Building on this foundation, SciVision has achieved a world-first innovation with its patented auto cross-linking technology—a cutting-edge advancement that completely eliminates the need for chemical cross-linking agents. We are currently the only company in the world capable of producing crosslinked hyaluronic acid without any chemical additives, marking a major leap forward in product purity, safety, and biocompatibility. With strong R&D capabilities and a commitment to innovation, SciVision is not only advancing hyaluronic acid technology—we are defining its future.

We uphold the concept and spirit of continuous innovation, based on science, create a better vision for mankind, and help people have health, happiness, and achieve a fulfilling life.

Production capability and five Competences

 

In order to meet the need for internationalization and capacity expansion, SciVision Biotech has two production sites, the Biotechnology 1 (BT1) factory and the Medical Device Plant (MD plant), both located in Kaohsiung Cianjhen Technology Industrial Park. The BT1 factory has one basement and seven floors above ground. It is qualified for Quality Management System (QMS) and ISO 13485 and complies with the US FDA and PIC/s GMP regulations. It is fully equipped with advanced automatic equipment. Excellent quality management systems and production capabilities attract cooperation from global partners.

size_1047x700
研發能力

R & D
Capability

CHAP專利技術

Patented CHAP 
Technology

知識與市場經驗

Knowledge and
Experiences

生產能力

Production
Capability

國際夥伴關係

International
Partnership

Annual Chronicle

The company was established on November 12, 2001.

2001
  • Company Established

     

2002
  • Received the Approval Letter from the Ministry of Economic Affairs Confirming Compliance with the Emerging Strategic Industries.
  • Completed the Development of the Microbial Fermentation Process for "Hyaluronic Acid."
2003
  • Patent Application for the "Purification Process of Hyaluronic Acid"
  • Program for Development of New Leading Products, Medical Grade Hyaluronic Acid, was Approved by the Ministry of Economic Affairs
2004
  • Awarded the “Investment Incentive Program” from the Kaohsiung City Government

     

2005
  • The Medical Device Plant was GMP Certified for the Class Ⅲ Medical Device by the Department of Health, Executive Yuan
  • Achieved the ISO 9001 and ISO 13485 Certification for Medical Device Quality Management System
  • Facial Dermal Implant without Lidocaine has Passed CE Certification
  • Awarded the “Product Innovation Leadership Award of the Biomedical Material Category” from the Frost & Sullivan Awards
  • Awarded the “Export Processing Zone Innovative Research and Development Award” from the Ministry of Economic Affairs

     

2006
  • Triple-Injection Synovial Fluid Supplement has Passed CE Certification
  • Triple-Injection Synovial Fluid Supplement Launched

     

2008
  • HYAJOINT Synovial Fluid Supplement has Passed the National Quality Certification and Received the Bronze Award in the Category of Medical and Healthcare Devices.

     

2009
  • Program for Development of New Leading Products, Facial Dermal Implant of Crosslinked Hyaluronan, was Approved by the Industrial Development Bureau, Ministry of Economic Affairs
  • The ITDP-Fast Track for Clinical Trial Program, HYADERMIS Clinical Trial Project, was Approved by the Ministry of Economic Affairs
  • Listed as Biotech and New Pharmaceutical Industry by the Ministry of Economic Affairs
  • The Small Business Innovation Research (SBIR), Single-Injection Synovial Fluid Supplement R&D Project, was Approved by the Kaohsiung City Government
  • Facial Dermal Implant without Lidocaine Launched

     

2010
  • China Patent for "Hyaluronic Acid and its Preparation Method" Granted
  • Listed on the Taipei Exchange (TPEx) with Emerging Stock Market Code 1786

     

2011
  • Taiwan Patent for " Method of Purifying Hyaluronic Acid" Granted
  • China Patent for the Technique of Cross-Linked Hyaluronic Acid Platform (CHAP) Granted

     

2012
  • Taiwan Patent for "Hyaluronic Acid Particles and their Preparation Method" Granted
  • Awarded the 9th“National New Innovation Award” from the Institute for Biotechnology and Medicine Industry
  • Awarded the 2nd“National Industry Innovation Award” from the Ministry of Economic Affairs
  • Single-Injection Synovial Fluid Supplement has Passed CE Certification
  • Single-Injection Synovial Fluid Supplement Launched
  • Approval of Taiwan Intellectual Property Management System (TIPS) Certification

     

2013
  • Taiwan and Japan Patent for the Technique of Cross-Linked Hyaluronic Acid Platform (CHAP) Granted
  • Facial Dermal Implant with Lidocaine in Particle Type Launched
  • IPOs (Initial Public Offerings) Launched in Taiwan

     

2014
  • Awarded the Outstanding Benchmark Award by the Kaohsiung City Government

     

2015
  • Approval of Subsidy Project of Investing Development and Promoting Industry from the Kaohsiung City Government

     

2016
  • U.S. Patent for the Technique of Cross-Linked Hyaluronic Acid Platform (CHAP) Granted

     

2017
  • Absorbable Adhesion Barrier for Pelvic, Obstetrics, and Gynecology Surgery Launched
  • Intravesical Instillation Launched

     

2018
  • Absorbable Adhesion Barrier for Tendon, Peripheral Nerve, and Joint Surgery Launched
  • Facial Dermal Implant with Lidocaine has Passed CE Certification
  • European Patent for the Technique of Cross-Linked Hyaluronic Acid Platform (CHAP) Granted

     

2019
  • Facial Dermal Implant with Lidocaine in Gel Type Launched
  • The Biotech Plant 1 is GMP Certified for the Class Ⅲ Medical Device by the Ministry of Health and Welfare, Republic of China (Taiwan)
  • Awarded the "16th National Brand Yushan Award" as an Outstanding Enterprise

     

2020
  • Stabilized Synovial Fluid Supplement Launched
  • Approval of Halal Assurance System (HAS)
  • PROTAHERE Absorbable Adhesion Barrier Won the Silver Award in “2020 Research and Development of Pharmaceutical Technology Award”
2021
  • The Company Headquarters has been Relocated to No.1, South 1st Rd., Qian Zhen Dist., Kaohsiung City 806, Taiwan (R.O.C.)

     

2022
  • Highly Efficient Synovial Fluid Supplement Launched

     

2023
  • Absorbable Adhesion Barrier for Obstetrics and Gynecology Surgery Launched

     

2024
  • CFS for Polycaprolactone (PCL) Dermal Implant
  • Poly-L-lactic acid (PLLA) launched
  • Taiwan Patent for the Method of Manufacturing Auto-Crosslinked Hyaluronic Acid Gel and Products Thereof Granted

Products and Services

 

SciVision Biotech has products in four high-end medical device fields, including HA dermal filler in the facial aesthetic field, absorbable adhesion barrier in the surgery field, synovial fluid supplement for the field of elderly care, and intravesical instillation in the field of urology. We provide comprehensive care for the beauty and health of the human race.

size_421x470
 

Dermal Implant

size_421x470
 

Synovial Fluid Supplement

size_421x470
 

Absorbable Adhesion Barrier

size_421x470

 

Intravesical Instillation

size_421x470
 

New Generation Composites Medical Devices

size_421x470
 

Customized Manufacturing Operations

Cookies Policy

This website uses browser records (Cookies) to provide you with the best experience. The Cookies we use also include third-party Cookies.

For related information, please visit ourprivacy policy. If you choose to continue browsing or close this prompt, you agree to our terms of website use.